We used submap analysis to compare the similarity between the gene signatures of the three ISs and melanoma patients treated with anti-PD1 and anti-CTLA4 (44), which revealed that IS3 patients were more sensitive to PD-1 inhibitors than the other two subtypes (Figure 3D). The gene discussed is CTLA4; the disease is melanoma.